© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jan 24, 2015, the consensus forecast amongst 32 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 24 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 125.00, with a high estimate of 150.00 and a low estimate of 84.00. The median estimate represents a 18.44% increase from the last price of 105.54. View Full Financials
Dividend information is not available for Gilead Sciences Inc. View Full Financials
On Oct 28, 2014, Gilead Sciences, Inc. reported 3rd quarter 2014 earnings of 2.05 per share. This result exceeded the 1.92 consensus of the 25 analysts covering the company and exceeded last year's 3rd quarter results by 1.53.
The next earnings announcement is expected on Feb 03, 2015. View Full Interim Financials
|Average growth rate||+55.30%|
Gilead Sciences, Inc. reported annual 2013 earnings of 2.04 per share on Feb 04, 2014.
The next earnings announcement from Gilead Sciences, Inc. is expected the week of Feb 03, 2015. View Full Annual Financials
|Average growth rate||+10.28%|
Gilead Sciences Inc. had 3rd quarter 2014 revenues of 6.04bn. This bettered the 5.99bn consensus of the 22 analysts covering the company. This was 7.55% below the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+23.88%|
Gilead Sciences Inc. had revenues for the full year 2013 of 11.20bn. This was 15.45% above the prior year's results. View Full Annual Financials
|Average growth rate||+12.51%|